12 / 38
Should we treat PDL1 neg NSCLC
+ Censored
Atezolizumab
Docetaxel
OAK:
Atezolizumab
vs
. Docetaxel
Months
Overall Survival (%)
Overall Survival (%)
mOS (mo)
Nivo
9.9
Doc
10.3
Time (months)
PD-L1<10%
HR (95% CI) = 1.00 (0.76, 1.31)
100
90
80
70
60
50
40
30
10
0
20
24
21
18
15
12
9
6
3
0
27
CHECKMATE 057:
Nivolumab
vs
. Docetaxel
TC0 and IC0
Gadgeel - ESMO 2017 * Borghaei – NEJM 2015